【摘 要】
：
Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (
【机 构】
：
Department of Oncology, Ward 2 Henan Cancer Hospital
【出 处】
：
第十八届全国临床肿瘤学大会暨2015年CSCO学术年会
论文部分内容阅读
Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (NSCLC) complicated with Coronary Heart Disease (CHD).
其他文献
Objective: A prospective phase Ⅱ trial was conducted to investigate the feasibility and safety of fractionated stereotactic radiotherapy (FSRT) combined with temozolomide (TMZ) for refractory brain me
目的：多形性胶质母细胞瘤(glioblastoma multiforme,GBM)是一种由不同表型和生物学行为的细胞亚群构成的高度异质性的病变,既往放射生物学研究多以单一细胞为对象,忽视了微环境下异质性细胞间的通讯和对话——即协同抵抗电离辐射的途径,难以实现临床转化。
目的：探讨桥本氏病合并甲状腺癌的发病机制、诊断和治疗。方法：对本院60例桥本氏甲状腺炎合并甲状腺癌患者的诊断检查和治疗过程进行回顾性分析，并作随访总结。结果：60例患者占同期收治的甲状腺癌例数的13％，占桥本氏甲状腺炎病例数的12％。
目的：淋巴结转移是甲状腺乳头状癌(Papillary Thyroid Carcinoma,PTC)治疗决策中的关键性因素。本研究的目的是寻找包括年龄在内的甲状腺微小乳头状癌(Papillary Thyroid MicroCarcinoma,PTMC)的风险因素。
目的：探讨动态监测131I治疗前刺激性甲状腺球蛋白(preablative stimulated thyroglobulin,ps-Tg)变化在伴有远处转移的分化型甲状腺癌(differentiated thyroid cancer,DTC)诊治中的意义。方法：317例甲状腺全切或次全切术后拟行131I治疗的DTC患者,根据是否存在远处转移(distant metastasis,DM)分为M1组(
目的：探讨甲状腺癌累及喉、气管时的外科处理。方法：2000-2010年我院手术治疗晚期分化型甲状腺癌20例，根据分化型甲状腺癌侵犯喉、颈段气管的范围及程度行肿瘤削除术、气管楔形切除缝合术、气管窗状切除胸锁乳突肌肌骨膜瓣修复术、气管袖状切除端端吻合术、气管袖状切除游离前臂皮瓣气管重建术；全喉切或近全切除术。
Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Combined blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4
Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NSCLC) in stage ⅢA-N2, but the side effect bec
Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), as first-linetreatments, contribu
Objective: To assess differences in overall survival among patients with NSCLC using TKIs in first or second line treatment and different TKIs.Method: Collecting patients data in CRF and use SPSS soft